AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9391999
Drug: Oral 17‐beta‐oestradiol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17‐beta‐oestradiol, 2 mg/day
Trial: 26805433
Drug: Oral inosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inosine
Trial: 20873243
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone (n=46)
Trial: 20873243
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and gliclaside MB (n=47)
Trial: 20873243
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and insulin (n=44)
Trial: 20873243
Drug: Insulin (n=45)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin (n=45)
Trial: 12477585
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine and ketamine (1 mg/mL)
Trial: 10361873
Drug: Danaparoid sodium
RxNorm normalized name: Danaparoid Sodium
DrugBank: Danaparoid (DB06754)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danaparoid sodium (750 anti-Xa units once daily for 8 weeks)
Trial: 8572838
Drug: Enalapril maleate,
RxNorm normalized name: Enalapril Maleate, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril maleate, 10 mg/d for 5 years
Trial: 7081684
Drug: Methylprednisolone 30
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 30 mg/kg administered following induction of anaesthesia and repeated with the start of cardiopulmonary bypass
Trial: 31041855
Drug: Blonanserin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blonanserin (8 to 24 mg/d)
Trial: 31041855
Drug: Haloperidol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (4 to 12 mg/d)
Trial: 27083200
Drug: Electroacupuncture +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture + Cognitive Behavioural Therapy (EA+CBT)
Trial: 24803302
Drug: AMG 181
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 181 (210 mg s.c.)
Trial: 24803302
Drug: AMG 181
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 181 (various doses: 0.7, 2.1, 7, 21, 70 mg s.c. or i.v., 210 mg s.c. or i.v., 420 mg i.v.)
Trial: 24803302
Drug: AMG 181
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 181 (various doses)
Trial: 14635749
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose (inj. hydrocortisone 100 mg IV 6‐hourly for 3 days)
Trial: 14635749
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose (inj. hydrocortisone 100 mg IV 6‐hourly on day 1, 100 mg IV 8‐hourly on day 2, and 100 mg IV 12‐hourly on day 3)
Trial: 14635749
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose protocol (inj. hydrocortisone 25 mg IV 6‐hourly on day 1, 25 mg IV 8‐hourly on day 2 and 25 mg IV 12‐hourly on day 3)
Trial: 11304719
Drug: r-HuEPO with
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-HuEPO with new stabilizer (glycine and Polysorbate 80) at 150 IU/kg sc dose
Trial: 11304719
Drug: r-HuEPO with
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-HuEPO with new stabilizer (glycine and Polysorbate 80) at 750 IU/kg sc dose
Trial: 11304719
Drug: r-HuEPO without
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-HuEPO without new stabilizer (HSA) at 150 IU/kg sc dose
Trial: 11304719
Drug: r-HuEPO without
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-HuEPO without new stabilizer (HSA) at 750 IU/kg sc dose
Trial: 11304719
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (with and without new stabilizer)
Trial: 31492718
Drug: Ladostigil 10
RxNorm normalized name: Ladostigil
DrugBank: Ladostigil (DB16213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ladostigil 10 mg/d
Trial: 29966612
Drug: Misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (200 μg, 4 times daily; n = 42)
Trial: 24650820
Drug: Prescription drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription drug misuse (PDM) of one class
Trial: 24650820
Drug: Prescription drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription drug misuse (PDM) of two classes
Trial: 24650820
Drug: Prescription drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription drug misuse (PDM) of three classes
Trial: 24650820
Drug: No prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prescription drug misuse (PDM)
Trial: 16219020
Drug: Recombinant leptin
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant leptin (10 mg/morning, 10 mg/evening, or 20 mg/day)
Trial: 7754943
Drug: No pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pacing therapy
Trial: 3965269
Drug: Domperidone (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (acute administration)
Trial: 7428183
Drug: Metoclopramide (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (acute administration)
Trial: 7428183
Drug: Metoclopramide (further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (further treatment)
Trial: 7428183
Drug: Domperidone (prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (prolonged administration)
Trial: 30529157
Drug: Phrenic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phrenic nerve infiltration with 10 mL of 0.25% bupivacaine
Trial: 26860018
Drug: Meloxicam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (15 mg) administered orally two hours before surgery
Trial: 26860018
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg) administered orally two hours before surgery
Trial: 1492847
Drug: Newly developed
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly developed effervescent granules (Imbun) containing 500 mg ibuprofen lysine salt (292.6 mg ibuprofen)
Trial: 1492847
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available granules containing 600 mg ibuprofen
Trial: 3884358
Drug: S-R theophylline
RxNorm normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-R theophylline preparation given once each night (mean 11.2 mg/kg/day)
Trial: 3884358
Drug: S-R aminophylline
RxNorm normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-R aminophylline preparation every 12 h (mean 10.3 mg theophylline/kg/day)
Trial: 26696365
Drug: PPI group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI group (lansoprazole 15 mg twice daily for 2 months)
Trial: 27428202
Drug: Atazanavir/ritonavir (ATV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir (ATV/r) monotherapy
Trial: 24445981
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate (40 mg/kg)
Trial: 16109088
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg alendronate, taken once a week for 6 weeks
Trial: 17488902
Drug: Chloroquine 50
RxNorm normalized name: chloroquine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 50 mg/kg
Trial: 3287881
Drug: Diltiazem (10-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (10-mg intravenous bolus followed by 15 mg/hr intravenous infusion during 72 hours, followed by 4 X 60 mg during 21 days)
Trial: 24914489
Drug: Standard cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive-behavioral group therapy (CBGT)
Trial: 21908466
Drug: Tablets moistened
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets moistened with 3 ml of normal saline
Trial: 21908466
Drug: Tablets moistened
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets moistened with 3 ml of 5% acetic acid
Trial: 21908466
Drug: Dry tablets
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry tablets
Trial: 18288734
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of mononuclear bone marrow cells (MBMC)
Trial: 11119395
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d
Trial: 8936545
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac 1 mg.kg‐1 without fentanyl
Trial: 8936545
Drug: Intravenous tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tenoxicam 0.4 mg.kg‐1 without fentanyl
Trial: 8936545
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac 1 mg.kg‐1 with fentanyl 0.75 microgram.kg‐1 i.v.
Trial: 8936545
Drug: Intravenous tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tenoxicam 0.4 mg.kg‐1 with fentanyl 0.75 microgram.kg‐1 i.v.
Trial: 29438373
Drug: Anlotinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib (12 mg per day, per os; days 1-14; 21 days per cycle)
Trial: 15353389
Drug: Risperidone (0.5-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5-1.5 mg/day)
Trial: 15353389
Drug: Haloperidol (0.5-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (0.5-1.5 mg/day)
Trial: 3119647
Drug: hCG/hMG treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG/hMG treatment (2500 IU hCG twice a week + 150 IU hMG three times a week for 13 weeks)
Trial: 3119647
Drug: Placebo (NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl only, same injection schedule)
Trial: 3119647
Drug: hCG/hMG treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG/hMG treatment
Trial: 27926631
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific treatment (group 3)
Trial: 20526206
Drug: BI 2536
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 2536 (200 mg on day 1)
Trial: 20526206
Drug: BI 2536
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 2536 (50 or 60 mg on days 1 to 3)
Trial: 18468955
Drug: 6000 mg
RxNorm normalized name: psyllium 6000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6000 mg chloride potassium dissolved in grape juice for 28 consecutive days
Trial: 16177196
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (500 mg calcium as carbonate, 3 times/d with meals)
Trial: 16177196
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules identical in appearance
Trial: 10047688
Drug: Chinese Hamster
RxNorm normalized name: Recombinant human antigen-specific polyclonal antibody (pAb) against RhD antigen expressed in Chinese hamster ovary cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese Hamster Ovary cell drived HB vaccine (CDV)
Trial: 10047688
Drug: Plasma drived
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma drived HB vaccine (PDV)
Trial: 8721550
Drug: High-dose ganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ganciclovir
Trial: 8721550
Drug: Combination foscarnet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination foscarnet and ganciclovir
Trial: 1376845
Drug: Isradipine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (0.4 mg)
Trial: 1376845
Drug: Nifedipine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (2.0 mg)
Trial: 6344896
Drug: Tienilic acid
RxNorm normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tienilic acid (mean daily dose 278 mg, range 125-500 mg)
Trial: 6344896
Drug: Conventional diuretics
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diuretics (mainly thiazide)
Trial: 6344896
Drug: Tienilic acid
RxNorm normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tienilic acid and Conventional diuretics
Trial: 26554360
Drug: High-dose target-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose target-controlled naloxone infusion
Trial: 19302911
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of anagrelide (2 mg/d, taken as 4 capsules)
Trial: 19302911
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of anagrelide
Trial: 19302911
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of anagrelide
Trial: 9558688
Drug: Nadolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (80 mg/day)
Trial: 2944268
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose cyproteronacetate plus lisuride (DoperginR)
Trial: 31230494
Drug: Direct release
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct release Mg2+ supplement (one phase)
Trial: 31230494
Drug: Delayed release
RxNorm normalized name: GRANULES, DELAYED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed release Mg2+ supplement (two phases)
Trial: 20377925
Drug: Wagyu beef
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wagyu beef (100 g)
Trial: 20377925
Drug: Kangaroo meat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangaroo meat (100 g)
Trial: 12050252
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg daily for 2 years
Trial: 11148939
Drug: Standardized, nonpunitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized, nonpunitive medication‐use variance process
Trial: 11148939
Drug: Traditional, multitiered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional, multitiered incident‐reporting system for medication errors
Trial: 9289431
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of ovarian neoplasms
Trial: 6120389
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oral prednisolone with azathioprine
Trial: 6120389
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral prednisolone with azathioprine
Trial: 22340989
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone and local betamethasone injected at the tongue base
Trial: 23440680
Drug: Fenoldopam (0.025-0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam (0.025-0.3 g/kg/min)
Trial: 16291413
Drug: Solifenacin 10
RxNorm normalized name: solifenacin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 10 mg QD for 10 days during the second cycle
Trial: 12479423
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with a 3 ml h(‐1) continuous infusion of fentanyl (2 microg) and bupivacaine (0.125%) for the first 3 days, with patient-controlled analgesia allowing an additional 5 ml of the same solution when pain score > 4.
Trial: 7629581
Drug: Protocol 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 1: infusion of 201Tl (111 MBq), insulin (5 U), potassium (10 mEq) in 10% glucose solution (250 ml)
Trial: 7629581
Drug: Protocol 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 2: infusion of 201Tl (111 MBq), potassium (10 mEq), insulin (5 U) in 5% glucose (250 ml)
Trial: 7033847
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg twice daily for 14 days
Trial: 26082085
Drug: Alginate-hydrogel in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate-hydrogel in combination with standard medical therapy
Trial: 23883807
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) nasal spray at 110 μg once daily for 12 weeks
Trial: 19297788
Drug: Alendronate (bisphosphonate),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (bisphosphonate), once-weekly treatment for 6 months
Trial: 19297788
Drug: Placebo treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment, once-weekly for 6 months
Trial: 17194255
Drug: Placebo (PLA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA; 34 g dextrose)
Trial: 17194255
Drug: Beta-alanine (b‐Ala;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (b‐Ala; 1.6 g b‐Ala plus 34 g dextrose)
Trial: 17194255
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (CrM; 5.25 g CrM plus 34 g dextrose)
Trial: 17194255
Drug: Beta-alanine plus
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine plus creatine (CrBA; 5.25 g CrM plus 1.6 g b‐Ala plus 34 g dextrose)
Trial: 12692611
Drug: Calcium phosphate
RxNorm normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium phosphate mouth rinse (Caphosol) with fluoride treatments
Trial: 12692611
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of fluoride rinsing and placebo tray treatments
Trial: 10584132
Drug: 200 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/m2 amifostine i.v., 30 minutes before radiation
Trial: 1877263
Drug: sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate 2 g q12h for five doses with ciprofloxacin 750 mg concurrently (Treatment A)
Trial: 1877263
Drug: ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin 750 mg administered two hours before the fifth dose of sucralfate (Treatment B)
Trial: 1877263
Drug: ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin 750 mg six hours before the fifth dose of sucralfate (Treatment C)
Trial: 1877263
Drug: ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin 750 mg alone (Treatment D)
Trial: 6311789
Drug: Ceftazidime (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (single dose preoperatively)
Trial: 6311789
Drug: Cefotaxime (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (three doses perioperatively)
Trial: 26320001
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care including medication (n = 60)
Trial: 19874474
Drug: INR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INR and prior doses
Trial: 15984968
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg od
Trial: 15984968
Drug: cisapride 20
RxNorm normalized name: cisapride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisapride 20 mg bid
Trial: 1672481
Drug: Celiprolol (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (200, 400, 600 mg once daily)
Trial: 1672481
Drug: Propranolol (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (total daily dose 80, 160, 320 mg twice daily)
Trial: 31629570
Drug: dPly/PhtD vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dPly/PhtD vaccine (10 µg dPly and 10 µg PhtD) co-administered with 13-valent PCV (PCV13)
Trial: 31629570
Drug: Placebo co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo co-administered with 13-valent PCV (PCV13)
Trial: 15836887
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rimonabant
Trial: 21869692
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg rimonabant
Trial: 12621596
Drug: Pentagastrin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentagastrin (0.2 micro g/kg)
Trial: 12621596
Drug: TRH (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH (600 or 1200 micro g)